Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Collegium Pharmaceutical Inc (COLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: COLL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.25
1 Year Target Price $41.25
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.21% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.04B USD | Price to earnings Ratio 26.52 | 1Y Target Price 41.25 |
Price to earnings Ratio 26.52 | 1Y Target Price 41.25 | ||
Volume (30-day avg) 5 | Beta 0.65 | 52 Weeks Range 23.23 - 42.29 | Updated Date 07/10/2025 |
52 Weeks Range 23.23 - 42.29 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.61% | Operating Margin (TTM) 13.71% |
Management Effectiveness
Return on Assets (TTM) 7.95% | Return on Equity (TTM) 19.23% |
Valuation
Trailing PE 26.52 | Forward PE 4.73 | Enterprise Value 1686560333 | Price to Sales(TTM) 1.57 |
Enterprise Value 1686560333 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 2.54 | Enterprise Value to EBITDA 5.07 | Shares Outstanding 32142200 | Shares Floating 27235365 |
Shares Outstanding 32142200 | Shares Floating 27235365 | ||
Percent Insiders 1.69 | Percent Institutions 117.12 |
Upturn AI SWOT
Collegium Pharmaceutical Inc
Company Overview
History and Background
Collegium Pharmaceutical, Inc. was founded in 2003. Initially focused on developing abuse-deterrent opioid products, it has evolved through acquisitions and pipeline development.
Core Business Areas
- Pain Management: Develops and commercializes products for the treatment of pain, with a focus on abuse-deterrent formulations and non-opioid pain relievers.
- Specialty Pharmaceutical: Focuses on specialized pharmaceutical products targeting specific patient populations and therapeutic areas.
Leadership and Structure
The company is led by a management team with experience in the pharmaceutical industry. The organizational structure consists of functional departments including R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Xtampza ER: Xtampza ER (oxycodone extended-release) is an abuse-deterrent opioid analgesic. Competitors include other extended-release opioids from companies like Purdue Pharma (bankruptcy), Teva Pharmaceuticals (TEVA), and Endo International (bankruptcy).
- Nucynta ER: Nucynta ER (tapentadol extended-release) is indicated for the management of severe chronic pain in adults when continuous, around-the-clock opioid treatment is needed for an extended period of time. The competitors are other extended release opioids from companies like Purdue Pharma (bankruptcy), Teva Pharmaceuticals (TEVA), and Endo International (bankruptcy).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition from generic drugs. The pain management segment faces challenges related to the opioid crisis and increasing demand for non-opioid alternatives.
Positioning
Collegium Pharmaceutical Inc. is positioned as a specialty pharmaceutical company with a focus on abuse-deterrent pain medications. Its competitive advantages lie in its proprietary technologies and targeted marketing strategies.
Total Addressable Market (TAM)
The TAM for pain management medications is substantial. Collegium Pharmaceutical Inc. aims to capture a share of this market through its differentiated product offerings. The total pain management market is estimated to be tens of billions of dollars annually, however, Collegium Pharmaceutical's specific TAM within this is smaller, based on its areas of focus.
Upturn SWOT Analysis
Strengths
- Abuse-deterrent technology
- Focused product portfolio
- Experienced management team
Weaknesses
- Reliance on opioid market
- Limited product pipeline diversity
- Small market capitalization
Opportunities
- Expansion into non-opioid pain treatments
- Strategic partnerships and acquisitions
- Geographic expansion
Threats
- Increasing regulatory scrutiny of opioids
- Competition from generic drugs
- Opioid crisis and potential litigation
Competitors and Market Share
Key Competitors
- TEVA
- ENDP
Competitive Landscape
Collegium Pharmaceutical Inc. faces competition from both branded and generic pharmaceutical companies. Its competitive advantage lies in its abuse-deterrent technology, but it needs to diversify its product portfolio.
Major Acquisitions
BioDelivery Sciences International, Inc.
- Year: 2022
- Acquisition Price (USD millions): 604
- Strategic Rationale: To expand its pain portfolio and pipeline with non-opioid pain management products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data not available without live data feeds. Requires API access.
Future Projections: Future growth projections data not available without live data feeds. Requires API access.
Recent Initiatives: Recent initiatives include product development efforts aimed at introducing new pain management solutions and expanding market presence.
Summary
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company focused on pain management, primarily known for abuse-deterrent opioid formulations. It is working to diversify its portfolio into non-opioid products. Regulatory scrutiny and litigation related to opioids pose challenges, but strategic acquisitions could support future growth. Diversification efforts are key to longer term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Financial data requires live data feeds. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collegium Pharmaceutical Inc
Exchange NASDAQ | Headquaters Stoughton, MA, United States | ||
IPO Launch date 2015-05-07 | CEO, President, Executive VP & Director Mr. Vikram Karnani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 357 | Website https://www.collegiumpharma.com |
Full time employees 357 | Website https://www.collegiumpharma.com | ||
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.